Designing Optimized, Site-Specific ADCs
Summary: Antibody-drug conjugates have provided a breakthrough in targeted medicines but ways of increasing their stability and efficacy are still required. Historically, the technologies used to build these two approved products result in a heterogeneous milieu of conjugates. These mixtures of ADCs have been plagued with manufacturing challenges due to batch-to-batch variability and complicated analytics.Catalent highlights how these goals can be achieved using its technology platforms to produce site-specific ADCs.
For more information, please download two more articles in the series:
- Whitepaper: Drug Development and Discovery April 2014
- Whitepaper: Bioprocess International October 2014